This study looks at two treatments for a type of cancer called mantle cell lymphoma (MCL). MCL is a cancer that affects your blood and bone marrow. The study compares two groups: one gets a special medicine called rituximab both with and without a procedure called a stem cell transplant. Rituximab is a medicine that helps stop cancer cells from growing. A stem cell transplant is where healthy cells are put back into your body to replace the ones destroyed by cancer treatment.

Patients in this study have MCL in first complete remission, meaning the cancer is not detectable after initial treatment. The goal is to see if adding a stem cell transplant helps patients live longer without the cancer coming back.

• The study lasts 10 years, with check-ups every 3 to 6 months.
• Participants may receive rituximab every 8 weeks for up to 18 treatments.
• Some risks include infections or the need for hospitalization.

Talk to your doctor if you have MCL and are interested in this study. They will check if you qualify and help you understand the risks and benefits.